Ardelyx confirms long-term safety of XPHOZAH for phosphate control in kidney disease patients on dialysis

Ardelyx presented data at the National Kidney Foundation's Spring Clinical Meetings showing that XPHOZAH (tenapanor) safely reduces serum phosphate without affecting other electrolytes in chronic kidney disease patients on dialysis. The analysis combined results from two clinical trials, NORMALIZE and OPTIMIZE, confirming no significant changes in nutrition, body mass, or blood pressure over extended use. This supports XPHOZAH's role as an effective add-on therapy for patients inadequately managed by phosphate binders. Ardelyx also hosted a peer exchange to discuss practical use and side effect management of XPHOZAH, which is taken twice daily and primarily causes mild to moderate diarrhea.